Skip to main content
Fig. 6 | Cancer Cell International

Fig. 6

From: ABCB1 and ABCG2 restricts the efficacy of gedatolisib (PF-05212384), a PI3K inhibitor in colorectal cancer cells

Fig. 6

Evaluation of SW620/GEDA, a resistance cell line created by gedatolisib. a Dose-viability curves of SW620 and SW620/GEDA cells after treatment with different concentration of gedatolisib for 72 h. b Dose-viability curves of SW620 and SW620/GEDA cells after treatment with different concentration of paclitaxel for 72 h. c Dose-viability curves of SW620 and SW620/GEDA cells after treatment with different concentration of doxorubicin for 72 h. d Dose-viability curves of SW620 and SW620/GEDA cells after treatment with different concentration of mitoxantrone for 72 h. e Dose-viability curves of SW620 and SW620/GEDA cells after treatment with different concentration of topotecan for 72 h. f Dose-viability curves of SW620 and SW620/GEDA cells after treatment with different concentration of cisplatin for 72 h. g The expression of ABCB1 and ABCG2 in SW620/GEDA cell line. Data were shown as mean ± SD, which is representative for three independent experiments. Asterisk presents when p value is < 0.05

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us